November 12, 2020 -- IsoPlexis has launched two new personalized lab systems, IsoSpark and IsoSpark Duo for high-throughput proteomics.
The new systems allow IsoPlexis to make its functional proteomics accessible to any labs, it said. IsoSpark features an 18-inch footprint and four-chip capacity, while IsoSpark Duo features an eight-chip capacity, according to the firm. The technologies provide end-to-end automation and highly multiplexed proteomics capabilities with increased scalability. The systems are fully compatible with IsoPlexis' full suite of applications and can be used for a number of applications including cancer immunology, infectious disease, cell therapy, targeted therapies, and inflammation.
IsoPlexis plans to begin shipping IsoSpark and IsoSpark Duo in January 2021.